GlassScriptPhysician profile
Elizabeth Mathes
NPI 1417347659
$4,892.18
in general payments reported to CMS, 2019-2025
38 companies · $1,286 in 2025
The $1,286 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $731 · 2023: $518 · 2024: $1,508 · 2025: $1,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $773.57 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $654.36 | 2021-2025 | |
| Lilly USA, LLC | $600.42 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $493.23 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $301.94 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Ardelyx, INC. | $176.89 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $171.11 | 2021-2025 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.21 | 2021-2025 | Jardiance, Synjardy |
| Inspiremd LTD | $147.33 | 2025 | Cguard Prime Carotid Stent System |
| Biohaven Pharmaceuticals, INC. | $143.68 | 2021 | |
| Phathom Pharmaceuticals, INC. | $136.89 | 2024 | Voquezna |
| Abbvie INC. | $130.94 | 2021-2023 | |
| Bausch Health US, LLC | $122.56 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $121.36 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corium, LLC | $97.48 | 2023 | Adlarity |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $88.92 | 2021 | |
| Esperion Therapeutics, INC. | $67.44 | 2021-2023 | Nexletol |
| Amarin Pharma, INC. | $44.87 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $42.14 | 2022 | |
| Vistapharm, INC. | $40.88 | 2021 | |
| Eisai INC. | $39.92 | 2021 | |
| Paratek Pharmaceuticals, INC. | $39.64 | 2022 | |
| Cequr Corporation | $30.09 | 2023 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $24.88 | 2021 | |
| Genentech USA, INC. | $24.76 | 2021 | |
| Dexcom, INC. | $20.19 | 2024 | Dexcom G6 Transmitter |
| Biocryst US Sales Co., LLC | $19.92 | 2022 | |
| Shield Therapeutics INC | $19.84 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $19.24 | 2023 | Rexulti |
| Medtronic, INC. | $17.64 | 2022 | |
| Acerus Pharmaceuticals Corporation | $17.14 | 2021 | |
| Pfizer INC. | $16.97 | 2023 | |
| Jazz Pharmaceuticals INC. | $16.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.93 | 2023 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.83 | 2022 | |
| Merck Sharp & Dohme LLC | $11.49 | 2021 | |
| Radius Health, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mathes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.